Chimeric antigen receptor T-cell therapy - Juno Therapeutics

Drug Profile

Chimeric antigen receptor T-cell therapy - Juno Therapeutics

Alternative Names: Armored CAR modified T Cells; CD19-directed 4-1BBL armored CAR - Juno Therapeutics; EGFRt/19-28z/4-1BBL CAR T cells

Latest Information Update: 04 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 15 Mar 2017 Phase-I clinical trials in Chronic lymphocytic leukaemia (Refractory metastatic disease, Recurrent) in USA (Parenteral) (NCT03085173)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top